MaveriX Oncology has developed the IMPACT-2X platform for the design of first-in-class small-molecule therapeutics—which are conditionally activated by highly expressed hydroxylases in cancer ...

The Werewolf technology uses design elements that address pharmaceutical, potency and tissue selectivity properties, previously a challenge for conditionally activated agents. Werewolf completed ...